Details for New Drug Application (NDA): 077317
✉ Email this page to a colleague
NDA 077317 describes ISRADIPINE, which is a drug marketed by Elite Labs Inc, Watson Labs Teva, and Norvium Bioscience, and is included in three NDAs. It is available from four suppliers. Additional details are available on the ISRADIPINE profile page.
The generic ingredient in ISRADIPINE is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.
The generic ingredient in ISRADIPINE is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.
Summary for 077317
| Tradename: | ISRADIPINE |
| Applicant: | Watson Labs Teva |
| Ingredient: | isradipine |
| Patents: | 0 |
Pharmacology for NDA: 077317
| Mechanism of Action | Calcium Channel Antagonists |
Medical Subject Heading (MeSH) Categories for 077317
Suppliers and Packaging for NDA: 077317
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ISRADIPINE | isradipine | CAPSULE;ORAL | 077317 | ANDA | Teva Pharmaceuticals USA, Inc. | 16252-539 | 16252-539-01 | 100 CAPSULE in 1 BOTTLE (16252-539-01) |
| ISRADIPINE | isradipine | CAPSULE;ORAL | 077317 | ANDA | Teva Pharmaceuticals USA, Inc. | 16252-540 | 16252-540-01 | 100 CAPSULE in 1 BOTTLE (16252-540-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 2.5MG | ||||
| Approval Date: | Jan 5, 2006 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
| Approval Date: | Jan 5, 2006 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
